Notably, Class IIa HDAC inhibitors attenuate inflammation in mouse and human macrophages,49, 53 stabilize atherosclerotic plaques in mice and limit the expression of inflammatory factors IL‐1β and IL‐6 in monocytes from patients with atherosclerosis, a chronic arterial inflammatory condition.53 This evidence concerns the gene IL6 and atherosclerosis.